Natural killer cell dysfunction in Uremia: The role of oxidative stress and the effects of dialysis

Blood Purification

Volumn 35, Issue , 2013, Pages 14-19

  Peraldi, Marie Noelle ^a,b,c   Berrou, Jeannig ^a,b   Métivier, Fabien ^b   Toubert, Antoine ^a,b,c  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

MICA; Natural killer cell; NKG2D; Oxidative stress; Polymethylmethacrylate; Uremia

Indexed keywords

ACRYLONITRILE; CD8 ANTIGEN; CELL ADHESION MOLECULE; CELL SURFACE MARKER; COPOLYMER; HLA ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D; POLY(METHYL METHACRYLATE); POLYSULFONE; PROTEIN MICA; UNCLASSIFIED DRUG;

ARTICLE; CD8+ T LYMPHOCYTE; CELL STRESS; CELL SUBPOPULATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIALYSIS; DIALYSIS MEMBRANE; END STAGE RENAL DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; MAJOR CLINICAL STUDY; MONOCYTE; NATURAL KILLER CELL; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UREMIA;

EID: 84877851375     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000350839     Document Type: Article

References (29)

1. Carrero JJ, Stenvinkel P: Inflammation in end-stage renal disease-what have we learned in 10 years? Semin Dial 2010; 23: 498-509.
2. Kaysen GA: Inflammation: cause of vascular disease and malnutrition in dialysis patients. Semin Nephrol 2004; 24: 431-436.
3. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfelds AB, Wolfe RA, Jones E, Disney AP, Briggs D, et al: Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 90-91.
4. Knerr K, Füth R, Hemsen P, Mohne W, Heinig A, Keophas W, Scherbaum WA, Martin S: Chronic inflammation and hemodialysis reduce immune competence of peripheral blood leucocytes in end-stage renal failure patients. Cytokine 2005; 30: 132-138.
5. Yoon JW, Pahl MV, Vaziri ND: Spontaneous leucocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney Int 2007; 71: 167-172.
6. Massry S, Smogorzewski M: Dysfunction of polymorphonuclear leukocytes in uremia: role of parathyroid hormone. Kidney Int 2001; 78:S195-S196.
7. Chatenoud L, Dugas B, Beaurain G, Touam M, Drueke T, Vasquez A, Galanaud B, Bach JF, Delfraissy JF: Presence of preactivated T cells in hemodialyzed patients: their possible role in altered immunity. Proc Natl Acad Sci USA 1996; 83: 7457-7461.
8. Meier P, Golshayan D, Blanc E, Pascual M, Burnier M: Oxidized LDL modulates apoptosis of regulatory T cells in patients with ESRD. J Am Soc Nephrol 2009; 20: 1368-1384.
9. Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND: Effects of end-stage renal disease on B-lymphocyte sub-populations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant 2010; 25: 205-212.
10. Deenitchina SS, Ando T, Okuda S, Kinukawa N, Hirakata H, Nagashima A, Fujishima M: Cellular immunity in hemodialysis patients: a quantitative analysis of immune cell subsets by flow cytometry. Am J Nephrol 1995; 15: 57-65.
11. Vaziri ND, Pahl MV, Crum A, Norris K: Effect of uremia on structure and function of immune system. J Ren Nutrition 2012; 22: 149-156.
12. Trinchieri G: Biology of natural killer cells. Adv Immunol 1989; 47: 187-201.
13. Lanier LL: Up on the tightrope natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495-502.
14. Champsaur M, Lanier LL: Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010; 235: 267-285.
15. Xia M, Guerra N, Sukhova GK, Yang K, Miller CK, Shi GP, Raulet DH, Xiong N: Immune activation resulting from NKG2D/ligand interaction promotes atherosclerosis. Circulation 2011; 124: 2933-2943.
16. Cooper MA, Fehniger TA, Caligiuri MA: The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-640.
17. Caligiuri MA: Human natural killer cells. Blood 2008; 112: 461-469.
18. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L: What is a natural killer cell? Nat Immunol 2002; 3: 6-8.
19. Norman PJ, Parham P: Complex interactions: the immunogenetics of human leukocyte antigen and killer cell immunoglobulin-like receptors. Semin Hematol 2005; 42: 65-75.
20. Lanier LL: NK cell recognition. Annu Rev Immunol 2005; 23: 225-274.
21. Zafirova B, Wensveen FM, Gulin M, Polic B: Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Life Sci 2011; 68: 3519-3529.
22. Nausch N, Cerwenka A: NKG2D in tumor immunity. Oncogene 2008; 27: 5944-5958.
23. Wu J: An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730-732.
24. Horng T, Bezbradica JS, Medzhitov R: NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway. Nat Immunol 2007; 8: 1345-1352.
25. Zwimmer NW, Dole K, Stastny N: Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. Hum Immunol 1999; 60: 323-330.
26. Tieng V, Le Bouguenec C, Du Merle L, Bertheau P, Desreumaux P, Janin A, Charron D, Toubert A: Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc Natl Acad Sci USA 2002; 99: 2977-2982.
27. Salih HR, Rammensee HG, Steinle A: Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169: 4098-4102.
28. Vacher-Coponat H, Brunet C, Lyonnet L, Bonnet E, Loundou A, Sampol J, Moal V, Dussol B, Brunet P, Berland Y, Dignat-George F, Paul P: Natural killer cell alterations correlate with loss of renal function and dialysis duration in uraemic patients. Nephrol Dial Transplant 2008; 23: 1406-1414.
29. Peraldi MN, Berrou J, Dulphy N, Seidowsky A, Haas P, Boissel N, Metivier F, Randoux C, Kossari N, Guérin A, Geffroy S, Delavaud G, Marin-Esteban V, Glotz D, Charron D, Toubert A: Oxidative stress mediates a reduced expression of the activating receptor NKG2D in NK cells from end-stage renal disease patients. J Immunol 2009; 182: 1696-1705.